Cyclin A1

Lucid Diagnostics Selected as Finalist for Medtech Company of the Year 2022 by Medical Device + Diagnostic Industry

Retrieved on: 
Thursday, December 8, 2022

I would like to thank the Medical Device + Diagnostic Industry editorial board for this honor, said Lishan Aklog, M.D.

Key Points: 
  • I would like to thank the Medical Device + Diagnostic Industry editorial board for this honor, said Lishan Aklog, M.D.
  • The MD+DI team carefully evaluated medical device and diagnostics companies that rose above the ranks over the past year and selected as Medtech Company of the Year 2022 Finalists those who have made tremendous strides in 2022.
  • The finalists include industry leaders such as Abbott Laboratories, Medtronic and ResMed, as well as newer groundbreaking companies such as BioIntelliSense and Senseonics.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

Retrieved on: 
Thursday, December 1, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that Suman M. Verma, M.D., Ph.D., Lucids Chief Scientific Officer, presented real-world data on its EsoCheck Cell Collection Device (EsoCheck) at the American Association for Cancer Researchs (AACR) Special Conference: Precision Prevention, Early Detection, and Interception of Cancer.
  • Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (EAC).
  • Over 80% of EAC patients die within five years of diagnosis, making it the second most lethal cancer in the U.S.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

Lucid Diagnostics Launches Stage II Lucid Test Center Expansion in California, Texas, Florida, and Ohio

Retrieved on: 
Thursday, August 11, 2022

The new Lucid Test Centers operate in leased medical office suites located in Lake Forest, California, Las Colinas, Texas, Delray Beach, Florida, and Columbus, Ohio.

Key Points: 
  • The new Lucid Test Centers operate in leased medical office suites located in Lake Forest, California, Las Colinas, Texas, Delray Beach, Florida, and Columbus, Ohio.
  • The Lake Forest Lucid Test Center is co-located with LucidDx Labs CLIA certified, CAP accredited commercial clinical laboratory.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • For more information, please visit www.luciddx.com , follow Lucid on Twitter , and connect with Lucid on LinkedIn .

Newly Published American Gastroenterological Association Clinical Practice Update Supports Esophageal Precancer Screening Using Lucid Diagnostics’ EsoGuard® and EsoCheck® Technologies

Retrieved on: 
Thursday, August 4, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that a recently published American Gastroenterological Association (AGA) clinical practice update supports esophageal precancer (Barretts Esophagus, BE) screening to prevent highly lethal esophageal cancer (EAC) utilizing its EsoGuard Esophageal DNA Test (EsoGuard) on samples collected with its EsoCheck Cell Collection Device (EsoCheck).

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that a recently published American Gastroenterological Association (AGA) clinical practice update supports esophageal precancer (Barretts Esophagus, BE) screening to prevent highly lethal esophageal cancer (EAC) utilizing its EsoGuard Esophageal DNA Test (EsoGuard) on samples collected with its EsoCheck Cell Collection Device (EsoCheck).
  • The clinical practice update entitled AGA Clinical Practice Update on New Technology and Innovation for Surveillance , the first such update since 2011, was recently published online in the journal, Clinical Gastroenterology and Hepatology.
  • The clinical practice update also significantly expands the target population for esophageal precancer screening, including for EsoGuard and EsoCheck, by recommending, for the first time, screening in at-risk patients without symptoms of reflux.
  • An updated American College of Gastroenterology clinical practice guideline and an American Gastroenterological Association clinical practice update both endorse nonendoscopic biomarker tests as an acceptable alternative to costly and invasive endoscopy for esophageal precancer screening.

Lucid Diagnostics’ Laboratory Executes Four New Participating Provider Agreements

Retrieved on: 
Tuesday, August 2, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that its wholly-owned CLIA-certified and CAP-accredited laboratory, LucidDx Labs Inc. (LucidDx Labs), has entered into participating provider agreements with preferred provider organizations Prime Healthcare , Three Rivers Provider Network , and Galaxy Health Network (the PPOs), as well as Alivio Health , a specialized diagnostic laboratory network.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid, the Company) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that its wholly-owned CLIA-certified and CAP-accredited laboratory, LucidDx Labs Inc. (LucidDx Labs), has entered into participating provider agreements with preferred provider organizations Prime Healthcare , Three Rivers Provider Network , and Galaxy Health Network (the PPOs), as well as Alivio Health , a specialized diagnostic laboratory network.
  • Our talented and expanding market access team will continue to work tirelessly to secure many more such agreements covering millions more lives.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • For more information, please visit www.luciddx.com , follow Lucid on Twitter , and connect with Lucid on LinkedIn .

Lucid Diagnostics’ Laboratory Executes Participating Provider Agreement with MediNcrease Health Plans

Retrieved on: 
Monday, May 9, 2022

As such, executing this, our first commercial payer agreement represents a very important milestone for the Company.

Key Points: 
  • As such, executing this, our first commercial payer agreement represents a very important milestone for the Company.
  • Millions of patients with GERD are at risk of developing esophageal precancer and a highly lethal form of esophageal cancer (EAC).
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).
  • For more information, please visit www.luciddx.com , follow Lucid on Twitter , and connect with Lucid on LinkedIn .

PAVmed Subsidiary Lucid Diagnostics Announces Launch of VA EsoGuard® Study

Retrieved on: 
Thursday, March 24, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center (Cleveland VA) have enrolled their first patient in a Department of Defense (DoD) funded study of its EsoGuard Esophageal DNA Test (EsoGuard) in at-risk patients with gastroesophageal reflux disease (GERD).

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center (Cleveland VA) have enrolled their first patient in a Department of Defense (DoD) funded study of its EsoGuard Esophageal DNA Test (EsoGuard) in at-risk patients with gastroesophageal reflux disease (GERD).
  • Lucid is providing EsoCheck Esophageal Cell Collection Devices (EsoCheck) for the study and will perform EsoGuard testing on the samples collected.
  • The study will enroll up to 100 Cleveland VA patients who fulfil the American College of Gastroenterology criteria for esophageal precancer screening.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

Retrieved on: 
Wednesday, March 23, 2022

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that it has launched Lucid Test Centers in three new metropolitan areasSeattle, Washington, Portland, Oregon, and Boise, Idaho.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid), a commercial-stage cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced that it has launched Lucid Test Centers in three new metropolitan areasSeattle, Washington, Portland, Oregon, and Boise, Idaho.
  • We now have completed the first stage of our Lucid Test Center program, an important pillar of our growth strategywith test centers in seven metropolitan areas in the Southwest and Pacific Northwest.
  • The new Lucid Test Centers operate in leased medical office suites located in Seattle, Washington, Portland, Oregon, and Boise, Idaho.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

PAVmed Subsidiary Lucid Diagnostics Launches LucidDx Labs to Accommodate EsoGuard Testing Growth

Retrieved on: 
Thursday, March 3, 2022

Having our own CLIA/CAP laboratory to perform EsoGuard testing will markedly streamline and simplify numerous important processes, including EsoGuard billing and collections.

Key Points: 
  • Having our own CLIA/CAP laboratory to perform EsoGuard testing will markedly streamline and simplify numerous important processes, including EsoGuard billing and collections.
  • More fundamentally, it provides us with a strong, long-term, scalable infrastructure to accommodate accelerating growth in testing volume from our expanding EsoGuard commercialization activities.
  • Concurrently, LucidDx Labs entered into an agreement to lease the building in Lake Forest, CA where the Laboratory operates from an affiliate of RDx.
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).

PAVmed Subsidiary Lucid Diagnostics Launches EsoGuard Telemedicine Program in Partnership with UpScriptHealth

Retrieved on: 
Wednesday, December 1, 2021

Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.

Key Points: 
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) (Lucid) a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (PAVmed), today announced it has launched its EsoGuard Telemedicine Program in partnership with UpScriptHealth, a leading, nationwide, direct-to-consumer telemedicine company.
  • We are fortunate to have an ideal partner in UpScriptHealth, a pioneer in online healthcare prescribing with a nationwide network of telemedicine physicians, as we look to expand the EsoGuard Telemedicine Program and Lucid Test Center network regionally and nationally.
  • Now, patients who respond to direct-to-consumer engagements can request video telemedicine evaluation through the EsoGuard Telemedicine Program by contacting 1-888-FOODTUBE or registering at www.EsoGuardConsultation.com .
  • Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM).